Veracyte (VCYT) EBT (2012 - 2026)

Veracyte has disclosed EBT across 15 years of filings, most recently posting $30.0 million for Q1 2026.

• EBT for Q1 2026 came in at $30.0 million, up 303.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.7 million (up 158.68% YoY), and the FY2025 annual result was $68.2 million, up 164.92% from the prior year.
• EBT came in at $30.0 million for Q1 2026 at Veracyte, down from $40.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of $40.6 million in Q4 2025 to a low of -$30.5 million in Q4 2023.
• The 5-year median for EBT is -$1.9 million (2024), against an average of $642235.3.
• Across the five-year window, EBT slumped 792.21% in 2023 and surged 1080.16% in 2025, its largest moves.
• Veracyte's EBT stood at -$3.4 million in 2022, then tumbled by 792.21% to -$30.5 million in 2023, then jumped by 111.3% to $3.4 million in 2024, then soared by 1080.16% to $40.6 million in 2025, then declined by 26.23% to $30.0 million in 2026.
• The last three EBT figures came in at $30.0 million (Q1 2026), $40.6 million (Q4 2025), and $18.9 million (Q3 2025), per Business Quant data.